ArticleInfluenza and other respiratory viruses2025
Influenza Vaccine Effectiveness During the 2023/2024 Season: A Test-Negative Case-Control Study Among Emergency Hospital Admissions With Respiratory Conditions in Northern Ireland.
Article in Influenza and other respiratory viruses, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Effectiveness of Influenza Vaccines and Duration of Protection Against Hospitalisation During the 2024/25 Season in Northern Ireland, UK.Influenza and other respiratory viruses · 2026Article
- Influenza Vaccine Effectiveness During the 2023/2024 Season: A Test-Negative Case-Control Study Among Emergency Hospital Admissions With Respiratory Conditions in Northern Ireland.Influenza and other respiratory viruses · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundWe evaluated the effectiveness of the influenza vaccine programme against infection among emergency hospital admissions with respiratory conditions in Northern Ireland during the 2023/2024 influenza season.
methodsUsing a test-negative design, we compared the odds of vaccination between patients who tested positive (cases) and negative (controls) for laboratory-confirmed influenza, adjusting for confounders. VE was stratified by age group, sex and time since vaccination.
resultsWe included 2368 hospitalised patients, of whom 1740 (73.5%) were influenza positive. Among these, 1703 (97.9%) were influenza A and 37 (2.1%) were influenza B. Of the influenza A-positive specimens, 84 were A(H1), 268 A(H3) and 1351 were untyped influenza A. VE against all laboratory-confirmed influenza was 47.5% (95% CI: 31.3%-60.1%), including 65.2% (95% CI: 44.2%-78.6%) in children aged 2-17, 46% (95% CI: 7.8%-68.2%) in adults 18-64 and 39.5% (95% CI: 4.8%-62.1%) in adults aged 65 and over. VE against infection for influenza A was 45.8% (95% CI: 25.1%-61%) in all age groups, but 64.7% (95% CI: 42.6%-78.6%) among children aged 2-17, 43.9% (95% CI: 3.7%-67.1%) among adults aged 18-64 years old and 39.6% (95% CI: 5%-62.1%) in adults aged ≥ 65 years. Being vaccinated was associated with 44.2% (95% CI: -13.3%-73.1%) and 37.9% (95% CI: 5.5%-59.5%) reduced odds of influenza A(H1) and A(H3)-associated community-acquired emergency admissions. VE against infection for influenza B was 87.2% (95% CI: 43.1%-98.3%). VE was highest within 2-8 weeks of vaccination at 67.5% (95% CI: 42.7%-81.7%) and declined to 41.2% (95% CI: 14.8%-59.5%) at 9-16 weeks.
conclusionsInfluenza vaccines provided protection against influenza-associated illness across age groups during the 2023/2024 influenza season.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.